TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors

Clinical Cancer Research

Volumn 19, Issue 13, 2013, Pages 3439-3449

  Ibberson, Mark ^a   Bron, Sylvian ^b   Guex, Nicolas ^a   Hull, Eveline Faes Van't ^b   Ifticene Treboux, Assia ^c   Henry, Luc ^b,e   Lehr, Hans Anton ^d   Delaloye, Jean François ^c   Coukos, George ^b   Xenarios, Ioannis ^a   Doucey, Marie Agnès ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d Institute of Pathology   (Germany)

^e EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; CD86 ANTIGEN; GLYCOPROTEIN P 15095; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; BREAST CANCER; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DENDRITIC CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MONOCYTE; MYELOID DENDRITIC CELL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; BREAST TUMOR; CLUSTER ANALYSIS; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANGIOGENESIS INHIBITORS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD11C; ANTIGENS, CD86; BREAST NEOPLASMS; CLUSTER ANALYSIS; DENDRITIC CELLS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MONOCYTES; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; RECEPTOR, TIE-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84879864448     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3181     Document Type: Article

References (33)

1. Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011;30:83-95.
2. Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011;11:702-11.
3. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162- 74.
4. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 2008;180:2011-7.
5. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, et al. Tie2 identifi es a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-26. (Pubitemid 41317592)
6. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007;109:5276-85. (Pubitemid 46890548)
7. Coffelt SB, Chen YY, Muthana M, Welford AF, Tal AO, Scholz A, et al. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J Immunol 2011;186:4183 -90.
8. Vesosky B, Hurwitz AA. Modulation of costimulation to enhance tumor immunity. Cancer Immunol Immunother 2003;52:663-9. (Pubitemid 37363636)
9. Yang G, Hellstrom KE, Chen L. The role of B7-2 (CD86) in tumour immunity. Expert Opin Investig Drugs 1997;6:677-84. (Pubitemid 27278217)
10. Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke XY, Rennert PD, et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 1995;2:523-32.
11. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:707-18.
12. Gervais A, Leveque J, Bouet-Toussaint F, Burtin F, Lesimple T, Sulpice L, et al. Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency. Breast Cancer Res 2005;7:R326-35.
13. Satthaporn S, Aloysius MM, Robins RA, Verma C, Chuthapisith S, McKechnie AJ, et al. Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha. BMC Immunol 2008;9:32.
14. Poindexter NJ, Sahin A, Hunt KK, Grimm EA. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res 2004;6:R408-15.
15. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999;190:1417-26.
16. Fainaru O, Almog N, Yung CW, Nakai K, Montoya-Zavala M, Abdollahi A, et al. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB J 2010;24:1411-8.
17. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012;72:2162-71.
18. Laurent J, Hull EF, Touvrey C, Kuonen F, Lan Q, Lorusso G, et al. Proangiogenic factor PIGF programs CD11b(+) myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors. Cancer Res 2011;71:3781-91.
19. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996;184:981- 92.
20. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008;205:2235-49.
21. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, et al. Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936-43. (Pubitemid 36889938)
22. Jin P, Han TH, Ren J, Saunders S, Wang E, Marincola FM, et al. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med 2010;8:4.
23. Pinzon-Charry A, Maxwell T, Lopez JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005;83:451-61. (Pubitemid 41805745)
24. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942- 9.
25. + lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol 2008;110:216-21.
26. Gupta S, Joshi K, Wig JD, Arora SK. Intratumoral FOXP3 expression in in filtrating breast carcinoma: its association with clinicopathologic parameters and angiogenesis. Acta Oncol 2007;46:792-7. (Pubitemid 47123764)
27. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011;475:226-30.
28. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
29. Della Porta M, Danova M, Rigolin GM, Brugnatelli S, Rovati B, Tronconi C, et al. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 2005;68:276-84. (Pubitemid 41158987)
30. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103. (Pubitemid 26338628)
31. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-7. (Pubitemid 36597102)
32. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203:871-81.
33. Kryczek I, Wei S, Zou L, Zhu G, Mottram P, Xu H, et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006;177:40-4. (Pubitemid 43939113)